Document Detail


Mifepristone and prostaglandin for termination of pregnancy: contraindications for use, reasons and rationale.
MedLine Citation:
PMID:  16781254     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Drug therapies are usually contraindicated in specific patient populations where evidence suggests that administration may result in a serious reaction or may seriously and negatively alter the risk benefit of treatment. There are few absolute contraindications to licensed regimens of mifepristone and prostaglandin for termination of pregnancy. However, those that are specified on "summary of product characteristics" [product labeling (PL)] differ from country to country. Differences reflect the dynamic environment of emerging scientific evidence, local experience and guidelines, and local regulatory processes, which all influence the resultant PL. The reasons and rationale for specific contraindications for mifepristone and prostaglandin for the termination of pregnancy are detailed, and the reasons for the differences between PL in different countries are explained.
Authors:
Angela Davey
Related Documents :
6735634 - The use of 15-methylated derivative of prostaglandin f2a for the therapeutic terminatio...
9589834 - Pilot study on the use of a two-week course of oral misoprostol in patients after termi...
4033154 - Speculations on the origin of the ill-effects associated with the use of visual display...
3282194 - Combined sonographic-pathologic surveillance in elective first-trimester termination of...
18059654 - Effect of the ratio of teaser rams used prior to breeding on the reproductive performan...
16931804 - Time trends in ectopic pregnancies in a norwegian county 1970-2004--a population-based ...
Publication Detail:
Type:  Historical Article; Journal Article     Date:  2006-05-06
Journal Detail:
Title:  Contraception     Volume:  74     ISSN:  0010-7824     ISO Abbreviation:  Contraception     Publication Date:  2006 Jul 
Date Detail:
Created Date:  2006-06-19     Completed Date:  2006-11-22     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0234361     Medline TA:  Contraception     Country:  United States    
Other Details:
Languages:  eng     Pagination:  16-20     Citation Subset:  IM    
Affiliation:
Exelgyn S.A, 216 Boulevard St. Germain, 75007 Paris. exelgyn.uk@btinternet.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Abortifacient Agents, Steroidal / administration & dosage,  contraindications*
Abortion, Induced / contraindications*,  methods*
Cardiovascular Diseases / chemically induced
Female
History, 20th Century
Humans
Legislation, Drug / history
Mifepristone / administration & dosage,  contraindications*
Pregnancy
Prostaglandins / administration & dosage,  contraindications*
Risk Factors
Chemical
Reg. No./Substance:
0/Abortifacient Agents, Steroidal; 0/Prostaglandins; 84371-65-3/Mifepristone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Women's perceptions on medical abortion.
Next Document:  Mifepristone dose in the regimen with misoprostol for medical abortion.